ArticleFrontiers in medicine2026
Influences of probiotics plus enteral nutrition on intestinal flora and inflammatory response in patients with severe acute pancreatitis.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Severe acute pancreatitis (SAP) is frequently accompanied by intestinal barrier disruption, systemic inflammation, and gut microbiota dysbiosis. Although enteral nutrition (EN) is standard in SAP management, EN alone may not fully restore the intestinal microenvironment. This study evaluated whether probiotics combined with EN improve intestinal mucosal integrity, inflammatory responses, immune status, nutritional indices, and intestinal flora in SAP patients. Methods: In this prospective, randomized, double-blind, placebo-controlled trial, 130 SAP patients were assigned to receive EN plus probiotics or EN plus placebo for 14 days. All patients received standardized supportive care and post-pyloric EN. Outcomes included time to abdominal pain relief, hospital stay, mortality, persistent organ failure, ICU utilization, intestinal mucosal barrier markers (endotoxin, diamine oxidase), inflammatory cytokines (CRP, TNF-α, IL-6), immune indicators (IgG, IgM, IgA), nutritional markers (prealbumin, albumin, transferrin), and quantitative fecal microbiota counts at baseline, day 7, and day 14. Statistical significance was defined as Results: Compared with controls, the probiotic group showed shorter abdominal pain relief time (4.21 ± 0.53 vs. 5.85 ± 0.62 days) and reduced hospital stay (20.02 ± 2.14 vs. 26.34 ± 3.25 days) (both Discussion: Probiotics combined with EN improved intestinal barrier function, inflammation, immunity, nutrition, and microbiota composition, although without reducing mortality or major complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.